



Market Announcement

13 October 2022

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited ('RAD') will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 17 October 2022 or when the announcement is released to the market.

Issued by

Angel He

Adviser, Listings Compliance (Sydney)

13 October 2022

Angel He
Adviser, Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Via email: tradinghaltssydney@asx.com.au

Dear Angel

Radiopharm Theranostics Limited (ASX: RAD)

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Radiopharm Theranostics Limited (ASX: RAD) (the **Company**) requests that its securities be placed into an immediate trading halt pending an announcement by the Company in relation to the release of Pivalate Phase II Data in Brain Mets Trial.

The Company requests that trading in its securities be halted until the earlier of the announcement to the market about the Pivalate Phase II Data in Brain Mets Trial and Monday 17 October.

The Company is not aware of any reason why this trading halt request should not be granted.

Please contact me if you require any further information.

Yours sincerely,

Phillip Hains
Company Secretary